<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1679-4974</journal-id>
<journal-title><![CDATA[Epidemiologia e Serviços de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Epidemiol. Serv. Saúde]]></abbrev-journal-title>
<issn>1679-4974</issn>
<publisher>
<publisher-name><![CDATA[Secretaria de Vigilância em Saúde e Ambiente - Ministério da Saúde do Brasil]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1679-49742017000400759</article-id>
<article-id pub-id-type="doi">10.5123/s1679-49742017000400008</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Perfil farmacoterapêutico dos usuários e gasto com medicamentos de alto custo em São Leopoldo, Rio Grande do Sul, Brasil, 2014]]></article-title>
<article-title xml:lang="es"><![CDATA[Perfil farmacoterapéutico de los usuarios y gasto en medicamentos de alto costo en São Leopoldo, Rio Grande do Sul, Brasil, 2014]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacotherapeutic profile of users and expenditure on high-cost drugs in São Leopoldo, Rio Grande do Sul State, Brazil, 2014]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sopelsa]]></surname>
<given-names><![CDATA[Mariani]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Motter]]></surname>
<given-names><![CDATA[Fabiane Raquel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barcellos]]></surname>
<given-names><![CDATA[Nêmora Tregnago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[Heloísa Marquardt]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Paniz]]></surname>
<given-names><![CDATA[Vera Maria Vieira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade do Vale do Rio dos Sinos  ]]></institution>
<addr-line><![CDATA[São Leopoldo RS]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>26</volume>
<numero>4</numero>
<fpage>759</fpage>
<lpage>770</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S1679-49742017000400759&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S1679-49742017000400759&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S1679-49742017000400759&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  OBJETIVO: descrever o perfil farmacoterapêutico dos usuários do Componente Especializado da Assistência Farmacêutica (CEAF) e mensurar os gastos com os medicamentos mais prevalentes e os mais onerosos.  MÉTODOS: estudo descritivo, realizado no município de São Leopoldo-RS, Brasil; utilizaram-se dados secundários sobre solicitações de medicamentos deferidas em 2014 via processo administrativo; para avaliar os custos, foram consultadas as guias de remessa da Secretaria de Estado da Saúde/RS.  RESULTADOS: foram incluídos 1.528 usuários, sobretudo mulheres (56,7%), e idade média de 52 anos (desvio-padrão=17,9); os diagnósticos mais frequentes foram asma alérgica (17,1%), doença renal crônica (11,5%) e artrite reumatoide (8,4%); o medicamento mais prevalente foi o fumarato de formoterol+budesonida (18,3%); o maior gasto total mensal entre os medicamentos mais prevalentes foi com alfaepoetina (R$37.922,34), e entre os mais onerosos, com infliximab (R$72.503,28).  CONCLUSÃO: os dados apontam para a importância do CEAF no tratamento de alto custo de morbidades com elevada prevalência.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: describir el perfil farmacoterapéutico de usuarios del Programa de Asistencia Farmacéutica Especializada (CEAF), y medir los costos de los medicamentos más comunes y más costosos.  MÉTODOS: estudio descriptivo realizado en São Leopoldo/RS, con datos secundarios sobre solicitudes de drogas diferidas en 2014 a través de procesos administrativos; para evaluar el costo, utilizamos las entregas de Secretaría Estatal de Salud/RS.  RESULTADOS: se incluyeron 1.528 usuarios, la mayoría mujeres (56,7%), edad media 52 años (desviación estándar=17,9); los diagnósticos más frecuentes fueron asma alérgica (17,1%), enfermedad renal crónica (11,5%) y artritis reumatoide (8,4%); la droga más frecuente fue budesónida+formoterol fumarato (18,3%); el mayor gasto total mensual de los fármacos más prevalentes fue con alfaepoetina (R$37.922,34) y entre los más caros, con infliximab (R$72.503,28).  CONCLUSIÓN: los datos señalan la importancia de este componente en el tratamiento de alto costo de morbilidad con altas prevalencias.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: to describe the pharmacotherapeutic profile of users of the Specialized Program for Pharmaceutical Assistance, and to measure the expenditure on the most prevalent and the most expensive medications.  METHODS: descriptive study conducted in São Leopoldo-RS, Brazil, with secondary data regarding information about requests accepted in 2014, through administrative proceedings; delivery notes of the State Health Department/RS were used to assess the costs.  RESULTS: 1,528 users were included in the study, mostly women (56.7%), and the average age was 52 years (standard deviation=17.9); the most frequent diagnoses were allergic asthma (17.1%), chronic kidney disease (11.5%) and rheumatoid arthritis (8.4%); the most prevalent drug was budesonide+formoterol fumarate (18.3%); among the most prevalent drugs, the highest total monthly expense was with epoetin alfa (BRL37,922.34) and among the most expensive drugs, infliximab (BRL72,503.28).  CONCLUSION: the data show the importance of the Specialized Program for Pharmaceutical Assistance in the high-cost treatment of highly prevalent.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Uso de Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Custos de Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Doença Crônica]]></kwd>
<kwd lng="pt"><![CDATA[Assistência Farmacêutica]]></kwd>
<kwd lng="pt"><![CDATA[Epidemiologia Descritiva]]></kwd>
<kwd lng="es"><![CDATA[Utilización de Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Costos de los Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad Crónica]]></kwd>
<kwd lng="es"><![CDATA[Servicios Farmacéuticos]]></kwd>
<kwd lng="es"><![CDATA[Epidemiología descriptiva]]></kwd>
<kwd lng="en"><![CDATA[Drug Utilization]]></kwd>
<kwd lng="en"><![CDATA[Drug Costs]]></kwd>
<kwd lng="en"><![CDATA[Chronic Disease]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical Services]]></kwd>
<kwd lng="en"><![CDATA[Epidemiology, Descriptive]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Políticas de Saúde. Departamento de Atenção Básica</collab>
<source><![CDATA[Política nacional de medicamentos]]></source>
<year>2000</year>
<page-range>40</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde. Conselho Nacional de Saúde</collab>
<article-title xml:lang=""><![CDATA[Resolução nº 338, de 06 de maio de 2004. Aprova a política nacional de assistência farmacêutica]]></article-title>
<source><![CDATA[Diário Oficial da República Federativa do Brasil]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
<source><![CDATA[Da excepcionalidade às linhas de cuidado: o componente especializado da assistência farmacêutica]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria GM/MS nº 2.577, de 27 de outubro de 2006. Aprova o componente de medicamentos de dispensação excepcional]]></article-title>
<source><![CDATA[Diário Oficial da República Federativa do Brasil]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Portaria GM/MS nº 1.554, de 30 de julho de 2013. Dispõe sobre as regras de financiamento e execução do componente especializado da assistência farmacêutica no âmbito do Sistema Único de Saúde (SUS)]]></article-title>
<source><![CDATA[Diário Oficial da República Federativa do Brasil]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos</collab>
<source><![CDATA[Componente especializado da assistência farmacêutica: inovação para a garantia do acesso a medicamentos no SUS]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sesso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Thomé]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Romão Junior]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Lugon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relatório do censo brasileiro de diálise crônica 2008]]></article-title>
<source><![CDATA[J Bras Nefrol]]></source>
<year>2008</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>233-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Acúrcio]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Cherchiglia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Júnior]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[EIG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos excepcionais para doença renal crônica: gastos e perfil de utilização em Minas Gerais, Brasil]]></article-title>
<source><![CDATA[Cad Saúde Pública]]></source>
<year>2011</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>357-68</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Fundação Instituto Brasileiro de Geografia e Estatística</collab>
<source><![CDATA[Censo Demográfico 2010]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Centro Brasileiro de Classificação de Doenças</collab>
<source><![CDATA[Classificação estatística internacional de doenças e problemas relacionados à saúde (CID-10)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[CMR]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Júnior]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Cherchiglia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[EIG]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Dias da Silva]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gastos do Ministério da Saúde do Brasil com medicamentos de alto custo: uma análise centrada no paciente]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2011</year>
<volume>14</volume>
<numero>5^sSuppl</numero>
<issue>5^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S71-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acurcio]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[CMR]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Júnior]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Cherchiglia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil demográfico e epidemiológico dos usuários de medicamentos de alto custo no Sistema Único de Saúde]]></article-title>
<source><![CDATA[Rev Bras Estud Popul]]></source>
<year>2009</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>263-82</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grochocki]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Pontarolli]]></surname>
<given-names><![CDATA[DRS]]></given-names>
</name>
<name>
<surname><![CDATA[Venson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Correr]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pontarolo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide]]></article-title>
<source><![CDATA[Rev Bras Reumatol]]></source>
<year>2012</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>208-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Instituto Brasileiro de Geografia e Estatística</collab>
<source><![CDATA[Pesquisa nacional por amostra de domicílios]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pastorino]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Accioly]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzellotti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[MCD]]></given-names>
</name>
<name>
<surname><![CDATA[Jacob]]></surname>
<given-names><![CDATA[CMA]]></given-names>
</name>
<name>
<surname><![CDATA[Grumach]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asma - aspectos clínico-epidemiológicos de 237 pacientes de um ambulatório pediátrico especializado]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>1998</year>
<volume>74</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-58</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moraes]]></surname>
<given-names><![CDATA[LSL]]></given-names>
</name>
<name>
<surname><![CDATA[Barros]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Takano]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Assami]]></surname>
<given-names><![CDATA[NMC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatores de risco, aspectos clínicos e laboratoriais da asma em crianças]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2001</year>
<volume>77</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>447-54</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morais-Almeida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pité]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asma e rinite no idoso: estudo epidemiológico nacional]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2014</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-42</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louzada-Junior]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[BDB]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ciconelli]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análise descritiva das características demográficas e clínicas de pacientes com artrite reumatóide no estado de São Paulo, Brasil]]></article-title>
<source><![CDATA[Rev Bras Reumatol]]></source>
<year>2007</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-90</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferraz]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Soarez]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ciconelli]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conduta no diagnóstico e tratamento dos pacientes com artrite reumatóide no Brasil - respostas dos médicos a um questionário de avaliação]]></article-title>
<source><![CDATA[Acta Reum Port]]></source>
<year>2009</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-51</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blumenauer]]></surname>
<given-names><![CDATA[BTBB]]></given-names>
</name>
<name>
<surname><![CDATA[Judd]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Burls]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cranney]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infliximab for the treatment of rheumatoid arthritis]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2002</year>
<numero>3</numero>
<issue>3</issue>
<page-range>CD003785</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Filipowicz-Sosnowska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schechtman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Szczepanski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kavanaugh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2006</year>
<volume>54</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1390-400</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carias]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Zucchi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos de dispensação excepcional: histórico e gastos do Ministério da Saúde do Brasil]]></article-title>
<source><![CDATA[Rev Saúde Pública]]></source>
<year>2011</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>233-40</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas</collab>
<source><![CDATA[Saúde mental no SUS: os centros de atenção psicossocial]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Brasília (DF) ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Carmagnani]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Programa saúde da família no Brasil: um enfoque sobre seus pressupostos básicos, operacionalização e vantagens]]></article-title>
<source><![CDATA[Saúde Soc]]></source>
<year>2001</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-53</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paiva]]></surname>
<given-names><![CDATA[DCP]]></given-names>
</name>
<name>
<surname><![CDATA[Bersusa]]></surname>
<given-names><![CDATA[AAS]]></given-names>
</name>
<name>
<surname><![CDATA[Escuder]]></surname>
<given-names><![CDATA[MML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avaliação da assistência ao paciente com diabetes e/ou hipertensão pelo Programa Saúde da Família do Município de Francisco Morato, São Paulo, Brasil]]></article-title>
<source><![CDATA[Cad Saúde Pública]]></source>
<year>2006</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>377-85</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerra Junior]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Acúrcio]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[EIG]]></given-names>
</name>
<name>
<surname><![CDATA[Cherchiglia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Cesar]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ciclosporina versus tacrolimus no transplante renal no Brasil: uma comparação de custos]]></article-title>
<source><![CDATA[Cad Saúde Pública]]></source>
<year>2010</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>163-74</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abbud-Filho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baptista]]></surname>
<given-names><![CDATA[MASF]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[DBM]]></given-names>
</name>
<name>
<surname><![CDATA[Figueiro]]></surname>
<given-names><![CDATA[JMG]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[VD]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[LFS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conversão para micofenolato de sódio em pacientes receptores de transplante renal em manutenção: análise multicêntrica retrospectiva]]></article-title>
<source><![CDATA[J Bras Transpl]]></source>
<year>2007</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>817-21</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blatt]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Farías]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico do Programa de Medicamentos Excepcionais do Estado de Santa Catarina - Brasil]]></article-title>
<source><![CDATA[Lat Am J Pharm]]></source>
<year>2007</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>776-83</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wiens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Correr]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Otuki]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Grochocki]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Pontarolli]]></surname>
<given-names><![CDATA[DRS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avaliação econômica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paraná]]></article-title>
<source><![CDATA[Physis]]></source>
<year>2011</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>359-76</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[RDC]]></given-names>
</name>
<name>
<surname><![CDATA[Zanini]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análise de custo do tratamento medicamentoso da artrite reumatóide]]></article-title>
<source><![CDATA[Rev Bras Cienc Farm]]></source>
<year>2008</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
